T1	PROC 46 60	Estudio fase 3
T2	CHEM 85 94	nivolumab
#1	AnnotatorNotes T2	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 96 106	elotuzumab
#2	AnnotatorNotes T3	C1832049; elotuzumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	CHEM 108 120	pomalidomida
#3	AnnotatorNotes T4	C2347624; pomalidomide; Organic Chemical · Pharmacologic Substance
T5	CHEM 123 135	dexametasona
#4	AnnotatorNotes T5	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T6	DISO 142 158	mieloma múltiple
#5	AnnotatorNotes T6	C0026764; Multiple Myeloma; Neoplastic Process
T7	PROC 182 219	Estudio fase 3, abierto, aleatorizado
T8	CHEM 245 254	nivolumab
#6	AnnotatorNotes T8	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	CHEM 256 266	elotuzumab
#7	AnnotatorNotes T9	C1832049; elotuzumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	CHEM 268 280	pomalidomida
#8	AnnotatorNotes T10	C2347624; pomalidomide; Organic Chemical · Pharmacologic Substance
T11	CHEM 283 295	dexametasona
#9	AnnotatorNotes T11	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T12	DISO 302 330	mieloma múltiple en recidiva
#10	AnnotatorNotes T12	C2349261; Relapse multiple myeloma; Neoplastic Process
T13	DISO 368 384	mieloma múltiple
#11	AnnotatorNotes T13	C0026764; Multiple Myeloma; Neoplastic Process
T14	DISO 411 439	mieloma múltiple en recidiva
#12	AnnotatorNotes T14	C2349261; Relapse multiple myeloma; Neoplastic Process
T15	DISO 482 500	Enfermedad medible
#13	AnnotatorNotes T15	C1513041; Measurable Disease; Disease or Syndrome
T16	PROC 536 547	tratamiento
#14	AnnotatorNotes T16	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T17	DISO 776 798	plasmocitoma solitario
#15	AnnotatorNotes T17	C0032131; Plasmacytoma; Neoplastic Process
T18	CHEM 593 616	fármaco inmunomodulador
T19	CHEM 629 652	inhibidor de proteosoma
#16	AnnotatorNotes T19	C1443643; Proteasome inhibitor; Pharmacologic Substance
T20	PROC 711 722	tratamiento
#17	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	ANAT 803 808	hueso
#18	AnnotatorNotes T21	C0262950; Skeletal bone; Body Part, Organ, or Organ Component | C0391978; Bone Tissue; Tissue
T22	DISO 828 866	leucemia activa de células plasmáticas
T23	ANAT 847 866	células plasmáticas
#19	AnnotatorNotes T23	C0032112; Plasma Cells; Cell
T24	DISO 870 915	gammapatía monoclonal de significado incierto
#20	AnnotatorNotes T24	C0026470; Monoclonal Gammopathy of Undetermined Significance; Neoplastic Process
T25	DISO 923 952	mieloma múltiple asintomático
T26	DISO 954 957	SMM
#21	AnnotatorNotes T26	C1531608; Smoldering myeloma; Neoplastic Process | C2585107; Asymptomatic Multiple Myeloma; Neoplastic Process
T27	DISO 960 971	amiloidosis
#22	AnnotatorNotes T27	C0002726; Amyloidosis; Disease or Syndrome | C0011560; Amyloid deposition; Disease or Syndrom
T28	DISO 1005 1022	síndrome de POEMS
T29	DISO 1073 1086	organomegalia
#23	AnnotatorNotes T29	C4054315; Organomegaly; Finding
T30	DISO 1024 1052	discrasia celular plasmática
T31	ANAT 1042 1052	plasmática
#24	AnnotatorNotes T31	C0032105; Plasma; Body Substance
T32	DISO 1057 1071	polineuropatía
#25	AnnotatorNotes T32	C0152025; Polyneuropathy; Disease or Syndrome
T33	DISO 1088 1102	endocrinopatía
#26	AnnotatorNotes T33	C0014130; Endocrine System Diseases; Disease or Syndrome
T34	CHEM 1104 1126	proteínas monoclonales
#27	AnnotatorNotes T34	C0700271; M Protein, multiple myeloma; Amino Acid, Peptide, or Protein · Immunologic Factor
T35	ANAT 1143 1147	piel
#28	AnnotatorNotes T35	C1123023; Skin; Body System | C1278993; Entire skin; Body System
T36	CHEM 618 622	IMID
T37	DISO 917 921	MGUS
T38	ANAT 1034 1041	celular
#29	AnnotatorNotes T38	C0007634; Cells; Cell | C1269647; Entire cell; Cell
T39	DISO 1129 1147	cambios en la piel
#30	AnnotatorNotes T39	C0421292; Skin symptom change; Finding
T40	ANAT 811 823	extramedular
T41	DISO 973 1002	macrobulinemia de Waldenstrom
T42	Date 13 17	2015
T43	Date 727 735	reciente
A1	Status T16 History_of
A2	Status T18 History_of
A3	Status T36 History_of
A4	Status T19 History_of
#31	AnnotatorNotes T1	C0282461; Phase 3 Clinical Trials; Research Activity
#32	AnnotatorNotes T7	C0282461; Phase 3 Clinical Trials; Research Activity + C1709323; Open Label Study; Research Activity + C0034656; Randomization; Research Activity
#33	AnnotatorNotes T18	C5544470; Immunomodulating Agents; Pharmacologic Substance 
#34	AnnotatorNotes T36	C5544470; Immunomodulating Agents; Pharmacologic Substance 
#35	AnnotatorNotes T22	C0023484; Leukemia, Plasma Cell; Neoplastic Process 
#36	AnnotatorNotes T37	C0026470; Monoclonal Gammopathy of Undetermined Significance; Neoplastic Process
#37	AnnotatorNotes T25	C1531608; Smoldering myeloma; Neoplastic Process | C2585107; Asymptomatic Multiple Myeloma; Neoplastic Process
#38	AnnotatorNotes T28	C0085404; POEMS Syndrome; Disease or Syndrome 
#39	AnnotatorNotes T30	C1136084; Plasma cell dyscrasia; Disease or Syndrome 
#40	AnnotatorNotes T43	C0332185; Recent; Temporal Concept
T44	Observation 895 906	significado
A5	Assertion T44 Speculated
#41	AnnotatorNotes T44	C2826293; Clinical Significance; Finding
T45	Spec_cue 907 915	incierto
R1	Combined_with Arg1:T2 Arg2:T3	
R2	Combined_with Arg1:T3 Arg2:T4	
R3	Combined_with Arg1:T4 Arg2:T5	
R4	Combined_with Arg1:T8 Arg2:T9	
R5	Combined_with Arg1:T9 Arg2:T10	
R6	Combined_with Arg1:T10 Arg2:T11	
T46	Quantifier_or_Qualifier 333 344	refractario
#42	AnnotatorNotes T46	C0205269; Unresponsive to Treatment; Functional Concept
R7	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T46	
T47	Quantifier_or_Qualifier 442 453	refractario
#43	AnnotatorNotes T47	C0205269; Unresponsive to Treatment; Functional Concept
R8	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T47	
T48	Quantifier_or_Qualifier 519 532	≥ de 2 líneas
R9	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T48	
T49	Quantifier_or_Qualifier 569 586	al menos 2 ciclos
R10	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T49	
R11	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T49	
R12	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T49	
R13	Combined_with Arg1:T18 Arg2:T19	
R14	Combined_with Arg1:T36 Arg2:T19	
R15	Used_for Arg1:T18 Arg2:T16	
R16	Used_for Arg1:T19 Arg2:T16	
T50	Quantifier_or_Qualifier 653 658	solos
R17	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T50	
R18	Overlap Arg1:T20 Arg2:T43	
T51	Observation 679 689	Progresión
#44	AnnotatorNotes T51	C1457868; Worse; Finding (?)
R19	Before Arg1:T20 Arg2:T51	
T52	Quantifier_or_Qualifier 765 775	únicamente
R20	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T52	
R21	Location_of Arg1:T21 Arg2:T17	
R22	Location_of Arg1:T40 Arg2:T17	
#45	AnnotatorNotes T40	C1517060; Extramedullary; Spatial Concept
R23	Location_of Arg1:T23 Arg2:T22	
R24	Speculation Arg1:T45 Arg2:T44	
R25	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T44	
R26	Has_Quantifier_or_Qualifier Arg1:T37 Arg2:T44	
R27	Location_of Arg1:T38 Arg2:T30	
R28	Location_of Arg1:T31 Arg2:T30	
R29	Overlap Arg1:T30 Arg2:T32	
R30	Overlap Arg1:T30 Arg2:T29	
R31	Overlap Arg1:T30 Arg2:T33	
R32	Overlap Arg1:T30 Arg2:T34	
R33	Overlap Arg1:T30 Arg2:T39	
R34	Location_of Arg1:T35 Arg2:T39	
R35	Overlap Arg1:T32 Arg2:T29	
R36	Overlap Arg1:T29 Arg2:T33	
R37	Overlap Arg1:T33 Arg2:T34	
R38	Overlap Arg1:T34 Arg2:T39	
R39	Overlap Arg1:T32 Arg2:T33	
R40	Overlap Arg1:T32 Arg2:T34	
R41	Overlap Arg1:T32 Arg2:T39	
R42	Overlap Arg1:T29 Arg2:T34	
R43	Overlap Arg1:T29 Arg2:T39	
R44	Overlap Arg1:T33 Arg2:T39	
R45	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T50	
R46	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T50	
#46	AnnotatorNotes T52	C0205171; Singular; Quantitative Concept
#47	AnnotatorNotes T41	C0024419; Waldenstrom Macroglobulinemia; Neoplastic Process
#48	AnnotatorNotes T50	C0205171; Singular; Quantitative Concept
